Skip Navigation

Leroy M. Parker, MD


Medical Oncology

Make an Appointment
Watch Video

Physician

  • Senior Physician
  • Associate Clinical Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Breast oncology
  • Clinical trials
  • General oncology
  • Hormonal therapy of cancer
  • New therapies

Diseases Treated

Contact Information

  • Appointments617-632-2175 (new)
    617-632-3800 (follow-up)
  • Office Phone Number617-632-3800
  • Fax617-632-1930

Bio

Dr. Parker earned his MD from Johns Hopkins University in 1969, and received postdoctoral training at Johns Hopkins Hospital and the National Institutes of Health. He trained in medical oncology at DFCI, joining the staff in 1973. His clinical focus is breast cancer, and he also conducts patient-related clinical research.

Board Certification:

  • Internal Medicine, 1973
  • Medical Oncology, 1975

Fellowship:

  • National Institute of Arthritis and Metabolic Diseases, National Institutes of Health, Rheumatology
  • Peter Bent Brigham Hospital, Medical Oncology
  • Sidney Farber Cancer Institute, Oncology

Residency:

  • Johns Hopkins School of Medicine, Internal Medicine

Medical School:

  • Johns Hopkins University School of Medicine

Research

Clinical Trials in Breast Cancer

Our group has a particular interest in endocrine therapy for breast cancer. We participated in a pivotal trial that resulted in the approval of fulvestrant, a pure antiestrogen and estrogen-receptor downregulator for the treatment of metastatic breast cancer resistant to tamoxifen therapy. We are now involved in two trials using fulvestrant in metastatic breast cancer. In one, fulvestrant is administered at twice the previous dose after a loading dose of 500 mg. Previous studies have shown this approach to be safe, so the purpose of this trial is to determine whether it is more effective. In a second study, we are testing estrogen priming as a means of increasing the response rate to this agent.In the MA27 trial, Dr. Parker is the site principal investigator at Dana-Farber. This multicenter, multinational trial compares the efficacy and toxicity of anastrozole with that of exemestane in postmenopausal patients with early breast cancer.We also have been involved in recent Dana-Farber chemotherapy trials utilizing traztuzumab in combination with paclitaxel (for neoadjuvant therapy) and vinorelbine (for both neoadjuvant therapy and metastatic disease). We completed a trial testing the utility of pegfilgrastim and darbepoitin in the support of dose-dense adjuvant chemotherapy. In this trial, clinicians administered four cycles of doxorubin plus cyclophosphamide and four cycles of paclitaxel at two-week intervals to more than 100 women with early breast cancer. Results showed that single injections of growth factors were safe and effective in preventing febrile neutropenia and reducing the need for red blood cell transfusions. In addition to these trials, we have been involved in the protocol titled Biomechanics of Metastases in Bone, a study to monitor the fracture risk of patients with metastatic breast cancer. In the past two years, over 1,000 breast cancer patients at Dana-Farber have been evaluated for metastatic cancer to the spine, and approximately 100 patients met the inclusion criteria for a prospective clinical study. In these patients, we demonstrated that the reduction in the load-carrying capacity of a bone with a lytic defect can be predicted noninvasively using computed tomography. We are considering using a similar methodology in studies of patients with multiple myeloma.Finally, we completed a clinical trial testing the safety and preliminary efficacy of a humanized monoclonal antibody in comparison to zoledronic acid against human parathyroid-related protein in the prevention of skeletal events in metastatic breast cancer.

Mayer EL, Gropper AB, Harris L, Gold JM, Parker L, Kuter I, Come S, Najita JS, Guo H, Winer EP, Burstein HJ. Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer. Clin Breast Cancer. 2015 Feb; 15(1):24-30.
View in: PubMed

Chen WY, Giobbie-Hurder A, Gantman K, Savoie J, Scheib R, Parker LM, Schernhammer ES. A randomized, placebo-controlled trial of melatonin on breast cancer survivors: impact on sleep, mood, and hot flashes. Breast Cancer Res Treat. 2014 Jun; 145(2):381-8.
View in: PubMed

Campos SM, Berlin ST, Parker LM, Chen WY, Bunnell CA, Atkinson T, Lee J, Matulonis U, Hirsch MS, Harris L, Krasner CN. Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer. Int J Clin Oncol. 2010 Aug; 15(4):390-8.
View in: PubMed

Snyder BD, Cordio MA, Nazarian A, Kwak SD, Chang DJ, Entezari V, Zurakowski D, Parker LM. Noninvasive Prediction of Fracture Risk in Patients with Metastatic Cancer to the Spine. Clin Cancer Res. 2009 Dec 15; 15(24):7676-7683.
View in: PubMed

Burstein HJ, Chen YH, Parker LM, Savoie J, Younger J, Kuter I, Ryan PD, Garber JE, Chen H, Campos SM, Shulman LN, Harris LN, Gelman R, Winer EP. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res. 2008 Dec 01; 14(23):7871-7.
View in: PubMed

Lin NU, Parker LM, Come SE, Burstein HJ, Haldoupis M, Ryabin N, Gelman R, Winer EP, Shulman LN. Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions. Invest New Drugs. 2007 Aug; 25(4):369-75.
View in: PubMed

Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, Anderson KS, Harris LN, Garber JE, Richardson AL, Schnitt SJ, Nikolsky Y, Gelman RS, Polyak K. Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007 Mar; 11(3):259-73.
View in: PubMed

Burstein HJ, Parker LM, Keshaviah A, Doherty J, Partridge AH, Schapira L, Ryan PD, Younger J, Harris LN, Moy B, Come SE, Schumer ST, Bunnell CA, Haldoupis M, Gelman R, Winer EP. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol. 2005 Nov 20; 23(33):8340-7.
View in: PubMed

Burstein HJ, Bellon JR, Galper S, Lu HM, Kuter I, Taghian AG, Wong J, Gelman R, Bunnell CA, Parker LM, Garber JE, Winer EP, Harris JR, Powell SN. Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer. Int J Radiat Oncol Biol Phys. 2006 Feb 01; 64(2):496-504.
View in: PubMed

Vansonnenberg E, Shankar S, Parker L, Cheung L, Morrison PR, Silverman SG, Igelhart D. Palliative radiofrequency ablation of a fungating, symptomatic breast lesion. AJR Am J Roentgenol. 2005 Mar; 184(3 Suppl):S126-8.
View in: PubMed

Robertson JF, Erikstein B, Osborne KC, Pippen J, Come SE, Parker LM, Gertler S, Harrison MP, Clarke DA. Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer. Clin Pharmacokinet. 2004; 43(8):529-38.
View in: PubMed

Piccart M, Parker LM, Pritchard KI. Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer. Ann Oncol. 2003 Jul; 14(7):1017-25.
View in: PubMed

Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, Parker LM, Ellisen LW, Kuter I, Gadd MA, Christian RL, Kennedy PR, Borges VF, Bunnell CA, Younger J, Smith BL, Winer EP. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol. 2003 Jan 01; 21(1):46-53.
View in: PubMed

Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002 Aug 15; 20(16):3386-95.
View in: PubMed

Griffiths CT, Parker LM, Lee S, Finkler NJ. The effect of residual mass size on response to chemotherapy after surgical cytoreduction for advanced ovarian cancer: long-term results. Int J Gynecol Cancer. 2002 Jul-Aug; 12(4):323-31.
View in: PubMed

Torosian M, O'Shaughnessy J, Parker LM, Vogel C. Fulvestrant: clinical application of an estrogen receptor downregulator. Clin Ther. 2002; 24 Suppl A:A31-40.
View in: PubMed

Parker LM. Sequencing of hormonal therapy in postmenopausal women with metastatic breast cancer. Clin Ther. 2002; 24 Suppl C:C43-57.
View in: PubMed

Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001 May 15; 19(10):2722-30.
View in: PubMed

Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer EP. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol. 2000 Mar; 18(6):1212-9.
View in: PubMed

Burstein HJ, Ramirez MJ, Petros WP, Clarke KD, Warmuth MA, Marcom PK, Matulonis UA, Parker LM, Harris LN, Winer EP. Phase I study of Doxil and vinorelbine in metastatic breast cancer. Ann Oncol. 1999 Sep; 10(9):1113-6.
View in: PubMed

Parker LM, Bornstein BA. Endocrine and cytotoxic therapies for the management of advanced local breast cancer. Current clinical investigation. Surg Oncol Clin N Am. 1995 Oct; 4(4):779-90.
View in: PubMed

Lamb CC, Eberlein TJ, Parker LM, Silver B, Harris JR. Results of radical radiotherapy for inflammatory breast cancer. Am J Surg. 1991 Sep; 162(3):236-42.
View in: PubMed

Parker LM, Boyages J, Eberlein TJ. Inflammatory Breast Cancer. in Harris JR, Hellman S, Henderson IC, Kinne DW ,editors, Breast Diseases. 1991; 775-82.
View in: PubMed

Henderson IC, Hayes DF, Parker LM, Love S, Garber JE, Recht A, Breitmeyer JB, Harris JR, Canellos GP. Adjuvant systemic therapy for patients with node-negative tumors. Cancer. 1990 May 01; 65(9 Suppl):2132-47.
View in: PubMed

Parker LM. Doctor-patient communication and ethical issues. J Clin Oncol. 1989 Sep; 7(9):1182-3.
View in: PubMed

Krag KJ, Canellos GP, Griffiths CT, Knapp RC, Parker LM, Welch WR, Klatt M, Andersen J. Predictive factors for long-term survival in patients with advanced ovarian cancer. Gynecol Oncol. 1989 Jul; 34(1):88-93.
View in: PubMed

Sheldon T, Hayes DF, Cady B, Parker L, Osteen R, Silver B, Recht A, Come S, Henderson IC, Harris JR. Primary radiation therapy for locally advanced breast cancer. Cancer. 1987 Sep 15; 60(6):1219-25.
View in: PubMed

Parker LM, Sheldon TA, Cady B. Inflammatory Breast Cancer. in Harris JR, Hellman S, Henderson IC, Kinne DW, editors, Breast Diseases. 1987; 57077.
View in: PubMed

Sheldon TA, Parker LM, Cady B. Management of Locally Advanced Breast Cancer. in Harris JR, Hellman S, Henderson IC, Kinne DW, editors, Breast Diseases. 1987; 563-70.
View in: PubMed

Upchurch KS, Parker LM, Scully RE, Krane SM. Differential cyclic AMP responses to calcitonin among human ovarian carcinoma cell lines: a calcitonin-responsive line derived from a rare tumor type. J Bone Miner Res. 1986 Jun; 1(3):299-304.
View in: PubMed

Parker LM, Burstein NA. Overall Principles of Cancer Management: Hormone Therapy. Cancer Manual. 1986; 82-5.
View in: PubMed

Parker LM, Griffiths CT, Knapp RC. Cancer of the Female Genital Tract. Cancer Manual. 1986; 222-40.
View in: PubMed

Griffiths CT, Parker LM. Cancer of the Ovary. in Knapp RC, Berkowitz RS, editors Gynecologic Oncology. 1986; 313-77.
View in: PubMed

Karp DD, Parker LM, Binder N, Tantravahi R, Smith BR, Ervin TJ, Canellos GP. Treatment of the blastic transformation of chronic granulocytic leukemia using high dose BCNU chemotherapy and cryopreserved autologous peripheral blood stem cells. Am J Hematol. 1985 Mar; 18(3):243-9.
View in: PubMed

Berek JS, Knapp RC, Hacker NF, Lichtenstein A, Jung T, Spina C, Obrist R, Griffiths CT, Berkowitz R, Parker L, Lagasse LD, Zighelboim J, Bast RC. Intraperitoneal chemotherapy of epithelial ovarian carcinoma with Corynebacterium parvum. Am J Obst Gynecol. 1985; 152:1003-10.
View in: PubMed

Rado TA, Bollekens J, St Laurent G, Parker L, Benz EJ. Lactoferrin biosynthesis during granulocytopoiesis. Blood. 1984 Nov; 64(5):1103-9.
View in: PubMed

Bast RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR, Knapp RC. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983 Oct 13; 309(15):883-7.
View in: PubMed

Takvorian T, Parker LM, Hochberg FH, Canellos GP. Autologous bone-marrow transplantation: host effects of high-dose BCNU. J Clin Oncol. 1983 Oct; 1(10):610-20.
View in: PubMed

Parker LM. Leukemia after treatment of ovarian cancer with alkylating agents. N Engl J Med. 1983 Jun 09; 308(23):1422.
View in: PubMed

Bast RC, Berek JS, Obrist R, Griffiths CT, Berkowitz RS, Hacker NF, Parker L, Lagasse LD, Knapp RC. Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum. Cancer Res. 1983 Mar; 43(3):1395-401.
View in: PubMed

Wu YJ, Parker LM, Binder NE, Beckett MA, Sinard JH, Griffiths CT, Rheinwald JG. The mesothelial keratins: a new family of cytoskeletal proteins identified in cultured mesothelial cells and nonkeratinizing epithelia. Cell. 1982 Dec; 31(3 Pt 2):693-703.
View in: PubMed

Parker LM, Lipton JM, Binder N, Crawford EL, Kudisch M, Levin MJ. Effect of acyclovir and interferon on human hematopoietic progenitor cells. Antimicrob Agents Chemother. 1982 Jan; 21(1):146-50.
View in: PubMed

Knapp RC, Cramer D, Easterday CL, Goldstein DP, Leavitt T, Marchant DJ, Nelson JH, Parker LM. Gynecologic Cancer. Cancer Manual. 1982; 212-31.
View in: PubMed

Antman KH, Parker LM, Goldstein JD, Skarin AT, D'Orsi CJ. Acute renal failure following intravenous pyelography (IVP) in a patient with diffuse hypergammaglobulinemia: a case report. Med Pediatr Oncol. 1982; 10(3):289-94.
View in: PubMed

Greenberg HM, Newburger PE, Parker LM, Novak T, Greenberger JS. Human granulocytes generated in continuous bone marrow culture are physiologically normal. Blood. 1981 Oct; 58(4):724-32.
View in: PubMed

Parker LM, Binder N, Gelman R, Richman CM, Weiner RS, Yankee RA. Prolonged cryopreservation of human bone marrow. Transplantation. 1981 Jun; 31(6):454-7.
View in: PubMed

Hochberg FH, Parker LM, Takvorian T, Canellos GP, Zervas NT. High-dose BCNU with autologous bone marrow rescue for recurrent glioblastoma multiforme. J Neurosurg. 1981 Apr; 54(4):455-60.
View in: PubMed

Greenberg HM, Parker LM, Newburger PE, Said J, Cohen GI, Greenberger JS. Corticosteroid dependence of continuous hemopoiesis in vitro with murine or human bone marrow. Haematol Blood Transfus. 1981; 26:289-93.
View in: PubMed

Pesando JM, Come SE, Stark J, Parker LM, Griffiths CT, Canellos GP. cis-Diamminedichloroplatinum(II) therapy for advanced ovarian cancer. Cancer Treat Rep. 1980 Oct-Nov; 64(10-11):1147-8.
View in: PubMed

Parker LM, Griffiths CT, Yankee RA, Canellos GP, Gelman R, Knapp RC, Richman CM, Tobias JS, Weiner RS, Frei E. Combination chemotherapy with adriamycin-cyclophosphamide for advanced ovarian carcinoma. Cancer. 1980 Aug 15; 46(4):669-74.
View in: PubMed

Kufe DW, Beardsley P, Karp D, Parker L, Rosowsky A, Canellos G, Frei E. High-dose thymidine infusions in patients with leukemia and lymphoma. Blood. 1980 Apr; 55(4):580-9.
View in: PubMed

Frei E, Blum RH, Pitman SW, Kirkwood JM, Henderson IC, Skarin AT, Mayer RJ, Bast RC, Garnick MB, Parker LM, Canellos GP. High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am J Med. 1980 Mar; 68(3):370-6.
View in: PubMed

Garnick MB, Blum RH, Canellos GP, Mayer RJ, Parker L, Skarin AT, Li FP, Henderson IC, Frei E. Phase I trial of bruceantin. Cancer Treat Rep. 1979 Nov-Dec; 63(11-12):1929-32.
View in: PubMed

Lowenthal IS, Parker LM, Greenblatt DJ, Brown BL, Samy TS. Pharmacokinetic analysis of neocarzinostatin in normal and tumor-bearing rodents. Cancer Res. 1979 May; 39(5):1547-51.
View in: PubMed

Griffiths CT, Parker LM, Fuller AF. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep. 1979 Feb; 63(2):235-40.
View in: PubMed

Parker LM, Griffiths CT, Yankee RA, Knapp RC, Canellos GP. High-dose methotrexate with leucovorin rescue in ovarian cancer: a phase II study. Cancer Treat Rep. 1979 Feb; 63(2):275-9.
View in: PubMed

Weiner RS, Richman CM, Yankee RA, Parker L. Clinical results of autotransplantation after nitrosourea therapy. Exp Hematol. 1979; 7 Suppl 5:384-8.
View in: PubMed

Greenberger JS, Sakakeeny M, Parker LM. In vitro proliferation of hemopoietic stem cells in long-term marrow cultures: principles in mouse applied to man. Exp Hematol. 1979; 7 Suppl 5:135-48.
View in: PubMed

Cotter SM, Parker LM. High-dose methotrexate and leucovorin rescue in dogs with osteogenic sarcoma. Am J Vet Res. 1978 Dec; 39(12):1943-5.
View in: PubMed

Bern MM, McDermott W, Cady B, Oberfield RA, Trey C, Clouse ME, Tullis JL, Parker LM. Intraaterial hepatic infusion and intravenous adriamycin for treatment of hepatocellular carcinoma: a clinical and pharmacology report. Cancer. 1978 Aug; 42(2):399-405.
View in: PubMed

Blum RH, Wittenberg BK, Canellos GP, Mayer RJ, Skarin AT, Henderson IC, Parker LM, Frei E. A therapeutic trial of maytansine. Cancer Clin Trials. 1978; 1(2):113-7.
View in: PubMed

Parker LM, Hirst M, Israel M. N-trifluoroacetyladriamycin-14-valerate: additional mouse antitumor and toxicity studies. Cancer Treat Rep. 1978 Jan; 62(1):119-27.
View in: PubMed

Tobias JS, Weiner RS, Giffiths CT, Richman CM, Parker LM, Yankee RA. Cryopreserved autologous marrow infusion following high dose cancer chemotherapy. Eur J Cancer. 1977 Mar 29; 13(3):269-77.
View in: PubMed

Curt GA, Tobias JS, Kramer RA, Rosowsky A, Parker LM, Tattersall MH. Inhibition of nucleic acid synthesis by the di-n-butyl ester of methotrexate. Biochem Pharmacol. 1976 Sep 01; 25(17):1943-6.
View in: PubMed

Tobias JS, Parker LM, Tattersall MH, Frei E. Adriamycin/cyclophosphamide and adriamycin/melphalan in advanced L1210 leukaemia. Br J Cancer. 1975 Aug; 32(2):199-207.
View in: PubMed

Frei E, Jaffe N, Tattersall MHN, Pitman SW, Parker LM. New approaches to methotrexate treatment. Seminars in Medicine of the Beth Israel Hospital. N Eng J Medicine. 1975; 298:846-51.
View in: PubMed

Pitman SW, Parker LM, Tattersall MHN, Frei E. Clinical trial of high-dose methorexate-citrovorum factor: toxicologic and therapeutic considerations. Cancer Chemotherapy Reports. 1975; 5:43-49.
View in: PubMed

Tattersall MHN, Parker LM, Pitman SW, Frei E. The clinical pharmacology of high-dose methotrexate. Cancer Chemotherapy Reports. 1975; 6:25-29.
View in: PubMed

Gelfand MC, Parker LM, Steinberg AD. Mechanism of allograft rejection in New Zealand mice. II. Role of a serum factor. J Immunol. 1974 Jul; 113(1):1-8.
View in: PubMed

Parker LM, Chused TM, Steinberg AD. Immunofluorescence studies on thymocytotoxic antibody from New Zealand Black mice. J Immunol. 1974 Jan; 112(1):285-92.
View in: PubMed

Chused TM, Steinberg AD, Parker LM. Enhanced antibody response of mice to polyinosinic-polycytidylic acid by antithymocyte serum and its age-dependent loss in NZB-W mice. J Immunol. 1973 Jul; 111(1):52-7.
View in: PubMed

Parker LM, Steinberg AD. The antibody response to polyinosinic polycytidylic acid. J Immunol. 1973 Mar; 110(3):742-51.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions

Top